Propanc Biopharma (NASDAQ:PPCB – Get Free Report) and Absci (NASDAQ:ABSI – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.
Institutional & Insider Ownership
52.0% of Absci shares are owned by institutional investors. 28.5% of Propanc Biopharma shares are owned by insiders. Comparatively, 10.5% of Absci shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Propanc Biopharma and Absci’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Propanc Biopharma | N/A | -151.28% | -109.53% |
| Absci | -6,450.76% | -66.32% | -57.01% |
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Propanc Biopharma | N/A | N/A | -$58.92 million | ($24.25) | -0.05 |
| Absci | $2.80 million | 467.70 | -$115.18 million | ($0.83) | -10.12 |
Propanc Biopharma has higher earnings, but lower revenue than Absci. Absci is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings and recommmendations for Propanc Biopharma and Absci, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Propanc Biopharma | 1 | 0 | 0 | 0 | 1.00 |
| Absci | 1 | 0 | 8 | 0 | 2.78 |
Absci has a consensus target price of $13.43, suggesting a potential upside of 59.86%. Given Absci’s stronger consensus rating and higher probable upside, analysts plainly believe Absci is more favorable than Propanc Biopharma.
Risk & Volatility
Propanc Biopharma has a beta of 3.52, meaning that its stock price is 252% more volatile than the S&P 500. Comparatively, Absci has a beta of 2.35, meaning that its stock price is 135% more volatile than the S&P 500.
Summary
Absci beats Propanc Biopharma on 8 of the 13 factors compared between the two stocks.
About Propanc Biopharma
Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.
About Absci
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Receive News & Ratings for Propanc Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Propanc Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
